GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
admin 25th April 2018 Uncategorised 0US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
More: GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
Source: News